TSMHT
EDIT icon

Thurston Springer Miller Herd & Titak’s Editas Medicine EDIT Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-205
Closed -$451 – 768
2025
Q2 		$451 Hold
205
– – ﹤0.01% 1562
2025
Q1 		$237 Hold
205
– – ﹤0.01% 1626
2024
Q4 		$260 Hold
205
– – ﹤0.01% 1289
2024
Q3 		$699 Hold
205
– – ﹤0.01% 1452
2024
Q2 		$957 Buy
+205
New +$1.16K ﹤0.01% 1389

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's EDIT Position: Q3 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Editas Medicine (EDIT) in Q3 2025, closing a stake of 205 shares — an estimated $451 sold.

Thurston Springer Miller Herd & Titak first reported a position in EDIT in Q2 2024 and held it in 5 quarters. The position peaked at $957 in Q2 2024. 193 funds tracked by Wall St. Rank hold EDIT as of Q3 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining Editas Medicine position as of Q3 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 205 Editas Medicine shares in Q3 2025, an estimated $451.
  • Thurston Springer Miller Herd & Titak first reported a position in Editas Medicine in Q2 2024 and held it in 5 quarters.
  • Thurston Springer Miller Herd & Titak's Editas Medicine position peaked at $957 in Q2 2024.
  • 193 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2025, filed 7 Oct 2025.